CAPA to Present Two Posters at the 2026 CRA Annual Scientific Meeting

The Canadian Arthritis Patient Alliance is pleased to be presenting two posters at the 2026 Canadian Rheumatology Association Annual Scientific Meeting, taking place April 16–19 in Halifax. CAPA’s President, Linda Wilhelm, will be attending the conference and...

CAPA’s Letter to the Federal Government on New Co-Payments Under the Interim Federal Health Program (IFHP)

[et_pb_section fb_built="1" _builder_version="4.16" global_colors_info="{}"][et_pb_row _builder_version="4.16" background_size="initial" background_position="top_left" background_repeat="repeat" global_colors_info="{}"][et_pb_column type="4_4" _builder_version="4.16"...

Broken Chains: Understanding Drug Shortages and Their Impact on Patients

Drug shortages are an ongoing and growing challenge in Canada—affecting not just supply chains, but the daily lives of people who rely on medications to stay well. Join the Canadian Arthritis Patient Alliance (CAPA) for a one-hour discussion on Wednesday, May 13, 2026...

New Report Highlights Impact of Drug Shortages on People Living with Arthritis Across Canada

Ottawa, ON — March 25, 2026 — As global pharmaceutical supply chains face growing pressure from geopolitical tensions, trade disruptions, and evolving industrial policies, a new report from the Canadian Arthritis Patient Alliance (CAPA) highlights how these systemic...

CAPA at the Clinical Trials Symposium 2026

CAPA Board member Lucy Kovalova-Woods and Patient Partner in Research Linda Hunter, MScN, PhD (C), presented a poster titled “A Practical Framework for Meaningful Patient Partner Engagement in Clinical Trials” at the Clinical Trials Symposium on February 17, 2026. The...